Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov/Dec;27(6):e698-e699.
doi: 10.1097/MJT.0000000000001056.

Lorlatinib-Associated Acute Respiratory Distress Syndrome

Shaurya Sharma  1 , Krishna Kommineni  1 , Sanwal Singh Mehta  1 , Harpriya Singh  2
Affiliations

Lorlatinib-Associated Acute Respiratory Distress Syndrome

Shaurya Sharma et al. Am J Ther. 2020 Nov/Dec.
No abstract available

PubMed Disclaimer

References

    1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–566.
    1. Zou HY, Friboulet L, Kodack DP, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell. 2015;28:70–81.
    1. Rothenstein JM, Letarte N. Managing treatment-related adverse events associated with ALK inhibitors. Curr Oncol. 2014;21:19–26.
    1. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of Crizotinib in patients with ALK-positive non-small cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011–1019.
    1. Kim D, Ahn MJ, Shi Y, et al. Updated results of a global phase II study with Crizotinib in advanced ALK-positive non-small-cell lung cancer (abstract). ASCO Meet Abstr. 2012;30:7533.

LinkOut - more resources